Recruiting

Cancer Immunotherapy

Sponsor:

Dartmouth-Hitchcock Medical Center

Code:

NCT06116032

Conditions

Cancer

Tumor, Solid

Hematologic Malignancy

Blood Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Methylation Cytometry

Study Details

Brief summary:

In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.

Conditions

Cancer

Tumor, Solid

Hematologic Malignancy

Blood Cancer

Study ID

NCT06116032

Start date

Oct 3, 2022

Status verified date

Dec, 2025

Completion date

Jan 1, 2029

Anticipated

Primary completion date

Jan 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
  • Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).

Exclusion Criteria:

  • Pregnant women/fetuses/neonates
  • Prisoners
  • Decision-impaired individuals

Study Design

Enrollment

1500 participants

Anticipated

Interventions and Outcome Measures

Arms

Standard of Care Checkpoint

Patients receiving standard of care FDA approved immunotherapy

Bone Marrow Transplant

Patients undergoing transplant for hematologic malignancy

CAR T

Patients undergoing CAR T therapy

Interventions

Methylation Cytometry

Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.

Primary outcome measure

  • Response to therapy [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Brock C Christensen, PhD

603-650-1827brock.c.christensen@dartmouth.edu

Hannah G Stolrow, BA

7205174950hannah.stolrow@dartmouth.edu

Locations

Dartmouth-Hitchcock Medical Center

Recruiting

Lebanon, New Hampshire, United States, 03756

Contacts

Hannah G Stolrow, BA

7205174950hannah.stolrow@dartmouth.edu

Principal Investigator:

Brock C Christensen, PhD

More Information

Sponsor

Dartmouth-Hitchcock Medical Center

Last update posted

Dec 16, 2025

Last verified

Dec, 2025

Keywords

  • Immunotherapy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Dartmouth-Hitchcock Medical Center on 2025-12-16.